Dyax Corp. Announces Third Quarter Financial Results; HAE program On Track To Begin Phase III Trial Before Year End; R&D

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2005--Dyax Corp. (Nasdaq: DYAX) today announced financial results for the third quarter ended September 30, 2005. The Company will host a webcast and conference call at 10 am (ET) this morning to discuss these financial results and corporate progress for the quarter, and to provide an update on the Company's lead DX-88 program in hereditary angioedema (HAE).

Back to news